Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
N. Göloglu, C. Özge, G. Polat, S. Akbayir, B. Tasdelen, E.S. Özgür, S. Atis Nayci, A. Ilvan (Mersin, Turkey). Diagnostic value of vascular endothelial growth factor, glycosaminoglycan, cathepsin S, cathepsin H in the discrimination of transudate exudate and benign malignant patients with pleural effusion. Eur Respir J 2012; 40: Suppl. 56, 4620

Member's Comments

No comment yet.

Related content which might interest you: Vascular endothelial growth factor (VEGF) in malignant and tuberculous pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001 The diagnostic value of vascular endothelial growth factor in pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 246s Year: 2004 Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Vascular endothelial growth factor in pleural effusions of different origin Source: Eur Respir J 2005; 25: 600-604 Year: 2005 Is pleural VEGF a useful parameter? Source: Annual Congress 2007 - Pleural malignancy Year: 2007 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma Source: Eur Respir J 2010; 36: 1099-1105 Year: 2010 The role of vascular endothelial growth factor in tuberculous and parapneumonic pleural effusions Source: Annual Congress 2008 - Pleural diseases and interventions Year: 2008 The value of IL6 in differentiation between malignant and non malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Diagnostic usefulness of C reactive protein levels in pleural effusions of malignant and non malignant origin Source: Eur Respir J 2007; 30: Suppl. 51, 431s Year: 2007 Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001 Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusions Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 Host-derived osteopontin is important for malignant pleural effusion formation Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Diagnostic approach in a patient with pleural effusion Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=131 Year: 2002 Prognostic significance of neutrophil predominance in pleural fluid in patients with malignant effusion Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Interleukin-8 and other mediators are related to tumour burden in malignant pleural effusions (MPE) Source: Eur Respir J 2007; 30: Suppl. 51, 103s Year: 2007 Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007 The diagnostic value of mucinous carcinoma - associated antigen (MCA) testin differentiation of malignant from benign pleural effusion (PE) Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004